Lilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bn
Next issueIssue 16 · Tue 29 Sep 

Trials

2025-522312-16-00

EU Clinical Trials Information System

Trial ID
T-ctis-2025-522312-16-00
Registry
EU Clinical Trials Information System
CTIS number
2025-522312-16-00
Asset
brenipatide (LY3537031)
Sponsor, as registered
Eli Lilly & Co.
Phase
Therapeutic confirmatory (Phase III)
Indication
Alcohol Use Disorder
Status
Authorised
Start date
27/02/2026
Primary completion
CTIS does not publish one.
Member states concerned
Belgium, Germany
Sites
10

Member states whose regulator has a decision on this trial.

euclinicaltrials.euctis registryverified 2026-09-15

Notes on the record

countries is memberStatesConcerned, i.e. every member state the trial is filed in; site_count sums trialSites across authorised Part II sections. primary_completion_date is EMPTY because CTIS does not publish a primary completion date; it is not unknown, it is not a field the registry has. Per-state authorisation is NOT recorded. Supersedes the row verified 2026-08-31. Record lastUpdated 10/09/2026, publishDate 2026-09-11; member states BE and DE, decisions (DE 2026-01-29, BE 2026-02-06) and site counts unchanged; the API does not expose what changed.

Company

Through brenipatide (LY3537031): Lilly

Cited in

Issues quoting 2025-522312-16-00 in their own text.